A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.

Trial Details

NCT ID
NCT07489716
Phase
PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SHR-1826
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Aged 18-75 years
  • ECOG performance status score of 0 or 1;
  • Histopathologically confirmed advanced or metastatic non-small cell lung cancer;
  • Participants must provide archived or fresh tumor tissue;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →